NUMERO: #20250036

Título: THERAPEUTIC INHIBITION OF BMI-1 IN MUCOEPIDERMOID CARCINOMA: AN IN VIVO STUDY

Nome do Apresentador: José Martins Figueredo JUNIOR

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Patologia Oral

Resumo: Background: Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor, and often exhibits resistance to conventional therapies. Cancer stem cells (CSCs), a small population with self-renewal, multipotency, and tumorigenic potential, contribute to this resistance. Inhibiting CSCs could prevent therapeutic evasion. Bmi-1 is a key regulator of CSC self-renewal, and also plays a role in chemoresistance and metastasis.

Objective: Testing the therapeutic inhibition of Bmi-1 to prevent chemoresistance in MEC.

Study design: MEC patient-derived xenografts in vivo were used to test a Bmi-1 inhibitor (PTC-596) combined or not with cisplatin and separated into short and long-term treatment groups. Western blotting was used to evaluate Bmi-1 protein expression. Flow cytometry was used to quantify the CSC fraction, using ALDH and CD44 staining.

Results: Treatment with PTC-596 and cisplatin combined reduced Bmi-1 expression in both short- and long-term. A significant decrease in the CSC population was seen in the combination treatment short-term, while tumor size was notably reduced in the long-term combination treatment.

Conclusion: These results demonstrate that PTC-596 and cisplatin combined effectively reduced the CSC population and tumor size, suggesting it may be a promising therapeutic option for MEC patients.

Funding: CAPES 88887.915926/2023-00 and FAPESP 2023/04287-4 (JMFJ) NIH/NIDCR R01-DE21139 (JEN).

Autor 1:  José Martins Figueredo JUNIOR

E-mail 1:  [email protected]

Autor 2:   Jaqueline Vaz VANINI

E-mail 2:  [email protected]

Autor 3 :  Fabio Daumas NUNES

E-mail 3:  [email protected]

Autor 4:  Jacques EDUARDO NÖR

E-mail 4:  [email protected]